Combination therapies of alk inhibitors
AssigneeNovartis AG
InventorsMalte Peters, David LEBWOHL, Jeffrey SCOTT, Nanxin LI, Yvonne LAU
Life of this patent
Estimating the term…
Abstract
A method of treating a cancer in a subject is disclosed, comprising administering to the subject an immunomodulator and a second therapeutic agent, wherein: (i) the immunomodulator is chosen from one or more of: an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule, and (ii) the second therapeutic agent is LDK378, thereby treating the cancer.
Claims53
A method of treating a cancer in a subject, comprising administering to the subject an immunomodulator and a second therapeutic agent, wherein:
- (i) the immunomodulator is chosen from one or more of:
- an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule, and
- (ii) the second therapeutic agent is LDK378,
- thereby treating the cancer.
A method of reducing growth, survival, or viability, or all, of a a cancer cell, comprising contacting the cell with an immunomodulator and a second therapeutic agent, wherein:
- (i) the immunomodulator is chosen from one or more of:
- an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule, and
- (ii) the second therapeutic agent is LDK378,
- thereby reducing the growth, survival, or viability of the cancer cell.
The method of claim 36, wherein the cancer is an NSCLC such asa Stage IIIB or IV NSCLC, or a relapsed locally advanced or metastatic NSCLC.
A composition comprising an immunomodulator such as one or more of:
- an activator of a costimulatory molecule or an inhibitor of an immune checkpoint molecule and LDK378.
A pharmaceutical combination comprising (i) LDK378, or a pharmaceutically acceptable salt thereof, and (ii) nivolumab, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.